FORGE THERAPEUTICS

Forge Therapeutics is a biotechnology company developing novel medicines by combining bio-inorganic with medicinal chemistry to target metalloproteins. Forge has developed a fundamentally new approach for the discovery of metalloprotein inhibitors by focusing first on the metal in the enzyme active site.

FORGE NEW CHEMISTRY

Distinct from traditional approaches for ‘hit’ discovery using high throughput screens, the FORGE approach starts with metal-ligand interactions to identify selective metal-binding pharmacophore fragments from our proprietary library.  Using bio-inorganic and medicinal chemistry principles, full-length inhibitors are developed using a novel fragment growth strategy incorporating computational and structural biology.

FORGE NEW MEDICINES

Shining a light on a problem from a different direction can reveal undiscovered solutions.
At FORGE, we are uniquely discovering compounds that have potential for first-in-class medicines.

FORGE LPXC PROGRAM

LpxC has been recognized as an attractive antibacterial target for more than the past 15 years as it is conserved across Gram-negative bacteria and not found in Gram-positive bacteria or human cells. However, a lack of suitable chemical starting points has hampered development progress. Forge has utilized its proprietary metal-binding pharmacophore (“MBP”) library and processes to identify potent inhibitors of LpxC that are safe and effective in an animal model of Gram-negative infection and are able to kill Gram-negative superbugs where other antibiotics are ineffective.

WE ARE FORGE

Forge was founded by leading bio-inorganic scientists and industry experts with the vision of creating a significant biotechnology company that couples pioneering metalloprotein technology with rigorous research to create life-saving medicines in areas of high unmet needs.

Click here for video

FORGE TEAM

Zachary Zimmerman, Ph.D.

Chief Executive Officer

David Puerta, Ph.D.

Chief Operating Officer and Vice President of Discovery

Esther van de Boom

CFO

Min Teng, Ph.D.

Senior Principal Scientist, Medicinal Chemistry

Konstantin Taganov, Ph.D.

Principal Scientist, Biology

Baskar Nammalwar, Ph.D.

Research Scientist, Synthetic Chemistry

Xiaoming Li, Ph.D.

Principal Scientist, Medicinal Chemistry

FOUNDERS

Seth Cohen, Ph.D.

Professor of Chemistry, University of California San Diego Click here to learn more

David Puerta, Ph.D.

Chief Operating Officer and Vice President of Discovery Click here to learn more

Zachary Zimmerman, Ph.D.

Chief Executive Officer Click here to learn more

ADVISORS

Mario Polywka

COO of Evotec

Tom Coll

Partner at Cooley LLC

John Schmid

former CFO of Auspex and Trius

Steve Worland, Ph.D.

CEO of eFFECTOR and former CEO of Anadys

ANTIBIOTIC DRUG DEVELOPMENT TEAM

Karen Joy Shaw, Ph.D.

former Trius, Johnson & Johnson, and Schering Plough; led microbiology strategy for Tedizolid

Michael Barbachyn, Ph.D.

former Director Antibacterial Chemistry at Pfizer & AstraZeneca; inventor of ZYVOX

Lynn Silver, Ph.D.

former Senior Investigator at Merck;
discovered LpxC and developed INVANZ

Robert Bonomo, M.D.

Case Western Reserve University,
Professor of Medicine and Microbiology Chief

Brad Spellberg, M.D.

Chief Medical Officer, Los Angeles County & University of Southern California Medical Center

Andrew Tomaras, Ph.D.

former LpxC program leader at Pfizer

Partners and Investors

evotec

tcalogohorizontal28229

Contact Us

Info@ForgeTherapeutics.com

Forge Therapeutics, Inc.

3210 Merryfield Row

San Diego, CA 92121

Visit Us On Twitter